Who Is the Best Hematopoietic Stem-Cell Donor for a Male Patient With Acute Leukemia?

Background Female donors for male recipients worsen the outcome of allogeneic hematopoietic stem-cell transplantation. We wanted to find out whether a male human leukocyte antigen (HLA)–matched unrelated donor (MUD, 8/8, n=2,014) might be an alternative to a female HLA-identical sibling donor (n=2,656) for male patients with acute leukemia. Methods This is a retrospective analysis from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Results The relative risk (RR) of acute graft-versus-host disease (GVHD) of grades II to IV was increased in the MUD group with acute myeloid leukemia (AML) (RR, 1.47; P<0.001) and acute lymphoblastic leukemia (ALL) (RR, 1.76; P<0.001). There was no difference in incidence of chronic GVHD and nonrelapse mortality between the two groups. Probability of relapse was lower in the MUD group than in the sibling group in patients with ALL (hazards ratio [HR], 0.75; P=0.04) but not in the AML patients (HR, 0.89; P=0.17). Survival was not different between the groups. Leukemia-free survival (LFS) was also similar in the sibling and MUD groups in patients with AML (HR, 1.01; P=0.81) or ALL (HR, 0.93; P=0.45). Factors significantly associated with reduced LFS included active disease, poor cytogenetics, age, year of hematopoietic stem-cell transplantation, reduced-intensity conditioning, and the use of antithymocyte globulin. Conclusion Male patients who received grafts from male MUDs demonstrated an increased incidence of acute GVHD and LFS same as when using HLA-identical female donors.

[1]  M. Kurokawa,et al.  The negative impact of female donor/male recipient combination in allogeneic hematopoietic stem cell transplantation depends on disease risk , 2011, Transplant international : official journal of the European Society for Organ Transplantation.

[2]  O. Ringdén,et al.  The allogeneic graft‐versus‐cancer effect , 2009, British journal of haematology.

[3]  M. Labopin,et al.  Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  H. Einsele,et al.  Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. , 2009, The Lancet. Oncology.

[5]  A. Barrett,et al.  The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. , 2009, Blood.

[6]  J. Bourhis,et al.  Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. , 2008, Experimental hematology.

[7]  A. Begovich,et al.  The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. , 2007, Blood.

[8]  Harriet Noreen,et al.  High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. , 2007, Blood.

[9]  G. Gahrton.  Risk assessment in haematopoietic stem cell transplantation: impact of donor-recipient sex combination in allogeneic transplantation. , 2007, Best practice & research. Clinical haematology.

[10]  J. Bourhis,et al.  Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Ce , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Porter,et al.  Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  J. Esteve,et al.  Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) , 2005, Leukemia.

[13]  Harriet Noreen,et al.  Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. , 2004, Blood.

[14]  V. Diehl,et al.  Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  F. Appelbaum,et al.  Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. , 2004, Blood.

[16]  J. Hansen,et al.  Tissue typing in support of unrelated hematopoietic cell transplantation. , 2003, Tissue antigens.

[17]  M. Labopin,et al.  Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Drijfhout,et al.  The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. , 2002, Blood.

[19]  B. Storer,et al.  Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors , 2002, Bone Marrow Transplantation.

[20]  J. Madrigal,et al.  Improving the outcome of unrelated donor stem cell transplantation by molecular matching. , 2001, Blood reviews.

[21]  C Anasetti,et al.  Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. , 2001, Blood.

[22]  G. Gustafsson,et al.  No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Disteche,et al.  The Human UTY Gene Encodes a Novel HLA-B8-Restricted H-Y Antigen1 , 2000, The Journal of Immunology.

[24]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[25]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[26]  K. Sullivan,et al.  Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. , 1997, Blood.

[27]  R Storb,et al.  Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. , 1997, Blood.

[28]  R. Arguello,et al.  Molecular histocompatibility typing in unrelated donor bone marrow transplantation. , 1997, Blood reviews.

[29]  A. Agulnik,et al.  The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. , 1997, Immunity.

[30]  A. Nademanee,et al.  The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. , 1995, Blood.

[31]  P. Ljungman,et al.  Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. , 1995, Bone marrow transplantation.

[32]  Ruth Etzioni,et al.  Marrow transplantation from unrelated volunteer donors. , 1995, Annual review of medicine.

[33]  O. Ringdén,et al.  Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease. , 1994, Clinical transplantation.

[34]  A. Rimm,et al.  Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. , 1990, Blood.

[35]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[36]  R. Hoffmann,et al.  Risk factors for acute graft‐versus‐host disease , 1987, British journal of haematology.

[37]  J. Biggs,et al.  Female marrow donors increase the risk of acute graft‐versus‐host disease: effect of donor age and parity and analysis of cell subpopulations in the donor marrow inoculum , 1986, British journal of haematology.

[38]  H. Deeg,et al.  Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. , 1983, Annals of internal medicine.

[39]  K. Sullivan,et al.  Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. , 1981, Blood.

[40]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.